Abstract: Small-cell carcinoma of the cervix (SCCC) is a rare neuroendocrine malignancy that accounts for 3%-5% of cervical cancer. It is a highly invasive cervical cancer characterized by early lymph node and hematogenous spread. Even if the lesion is clinically limited in the pelvis, the prognosis is also very poor. The 5-year overall survival rate for women in the FIGOⅠ-ⅡA period was 36.8%. The overall survival rate of SCCC patients with extensive metastasis was 0 in 5 years, and recurrent disease is incurable, and the survival time after diagnosis of recurrent disease is very short, usually only 7-8 months. SCCC often metastasizes rapidly to the lungs, liver, brain, bone, pancreas, and lymph nodes, leading to treatment failure in most cases. The treatment of SCCC is mainly based on surgery combined with radiotherapy and chemotherapy. Now we review its non-surgical treatment methods of SCCC and improve the prognosis of patients.

Key words: Uterine cervical neoplasms, Carcinoma, small cell, Antineoplastic combined chemotherapy protocols, Radiotherapy, Small-cell carcinoma of the cervix